Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding

Journal of Biological Chemistry

Volumn 289, Issue 19, 2014, Pages 13492-13502

  Andersen, Jan Terje ^a,b   Dalhus, Bjørn ^b   Viuff, Dorthe ^c   Ravn, Birgitte Thue ^d   Gunnarsen, Kristin Støen ^a   Plumridge, Andrew ^c   Bunting, Karen ^c   Antunes, Filipa ^d   Williamson, Rebecca ^c   Athwal, Steven ^c   Allan, Elizabeth ^c   Evans, Leslie ^c   Bjørås, Magnar ^b   Kjærulff, Søren ^c   Sleep, Darrell ^c   Sandlie, Inger ^a   Cameron, Jason ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Novozymes Biopharma DK A S   (United Kingdom)

^d NOVOZYMES A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; MAMMALS;

BIOPHARMACEUTICALS; CYNOMOLGUS MONKEYS; INTRACELLULAR DEGRADATION; NEONATAL FC RECEPTORS; PH-DEPENDENT; SINGLE-POINT MUTATION; THERAPEUTIC USE; TRANSGENICS;

BODY FLUIDS;

ALBUMIN; FC RECEPTOR; NEONATAL FC RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACEUTICS; PLASMA HALF LIFE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION;

ALBUMIN; ANIMAL MODELS; ANTIBODY ENGINEERING; BIODEGRADATION; BIOENGINEERING; FC RECEPTORS; PH REGULATION; PHARMACOKINETICS;

ALBUMINS; AMINO ACID SUBSTITUTION; ANIMALS; FEMALE; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MACACA FASCICULARIS; MICE; MUTATION, MISSENSE; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS;

EID: 84900437074     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.549832     Document Type: Article

References (36)

1. Montoyo, H. P., Vaccaro, C., Hafner, M., Ober, R. J., Mueller, W., and Ward, E. S. (2009) Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc. Natl. Acad. Sci. U. S. A. 106, 2788-2793
2. Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., and Anderson, C. L. (2003) The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197, 315-322
3. Simister, N. E., and Mostov, K. E. (1989) Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harbor Symp. Quant. Biol. 54, 571-580
4. Story, C. M., Mikulska, J. E., and Simister, N. E. (1994) A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulinG from mother to fetus. J. Exp. Med. 180, 2377-2381
5. Burmeister, W. P., Huber, A. H., and Bjorkman, P. J. (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372, 379-383
6. West, A. P., Jr., and Bjorkman, P. J. (2000) Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39, 9698-9708
7. Andersen, J. T., Dee Qian, J., and Sandlie, I. (2006) The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur. J. Immunol. 36, 3044-3051
8. Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., and Anderson, C. L. (2006) Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 45, 4983-4990
9. Kim, J. K., Firan, M., Radu, C. G., Kim, C. H., Ghetie, V., and Ward, E. S. (1999) Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol. 29, 2819-2825
10. Andersen, J. T., Dalhus, B., Cameron, J., Daba, M. B., Plumridge, A., Evans, L., Brennan, S. O., Gunnarsen, K. S., Bjørås, M., Sleep, D., and Sandlie, I. (2012) Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat. Commun. 3, 610
11. Schmidt, M. M., Townson, S. A., Andreucci, A. J., King, B. M., Schirmer, E. B., Murillo, A. J., Dombrowski, C., Tisdale, A. W., Lowden, P. A., Masci, A. L., Kovalchin, J. T., Erbe, D. V., Wittrup, K. D., Furfine, E. S., and Barnes, T. M. (2013) Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure 21, 1966-1978
12. Kobayashi, K., Qiao, S. W., Yoshida, M., Baker, K., Lencer, W. I., and Blumberg, R. S. (2009) An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology 137, 1746-1756
13. Akilesh, S., Christianson, G. J., Roopenian, D. C., and Shaw, A. S. (2007) Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol. 179, 4580-4588
14. Chan, A. C., and Carter, P. J. (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10, 301-316
15. Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J., and Ward, E. S. (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15, 637-640
16. Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., and Tsurushita, N. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279, 6213-6216
17. Vaccaro, C., Zhou, J., Ober, R. J., and Ward, E. S. (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23, 1283-1288
18. Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W., Sproule, T. J., Lazar, G. A., Roopenian, D. C., and Desjarlais, J. R. (2010) Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157-159
19. Andersen, J. T., Daba, M. B., and Sandlie, I. (2010) FcRn binding properties of an abnormal truncated analbuminemic albumin variant. Clin. Biochem. 43, 367-372
20. Elsadek, B., and Kratz, F. (2012) Impact of albumin on drug delivery: new applications on the horizon. J. Control. Release 157, 4-28
21. Sleep, D., Cameron, J., and Evans, L. R. (2013) Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta 1830, 5526-5534
22. Andersen, J. T., Cameron, J., Plumridge, A., Evans, L., Sleep, D., and Sandlie, I. (2013) Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J. Biol. Chem. 288, 24277-24285
23. Santagostino, E., Negrier, C., Klamroth, R., Tiede, A., Pabinger-Fasching, I., Voigt, C., Jacobs, I., and Morfini, M. (2012) Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 120, 2405-2411
24. Andersen, J. T., Daba, M. B., Berntzen, G., Michaelsen, T. E., and Sandlie, I. (2010) Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem. 285, 4826-4836
25. Andersen, J. T., Justesen, S., Fleckenstein, B., Michaelsen, T. E., Berntzen, G., Kenanova, V. E., Daba, M. B., Lauvrak, V., Buus, S., and Sandlie, I. (2008) Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. FEBS J. 275, 4097-4110
26. Evans, L., Hughes, M., Waters, J., Cameron, J., Dodsworth, N., Tooth, D., Greenfield, A., and Sleep, D. (2010) The production, characterisation and enhanced pharmacokinetics of scFv-Albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr. Purif. 73, 113-124
27. Böhm, G., Muhr, R., and Jaenicke, R. (1992) Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng. 5, 191-195
28. Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., and Roopenian, D. C. (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol. 18, 1759-1769
29. Sugio, S., Kashima, A., Mochizuki, S., Noda, M., and Kobayashi, K. (1999) Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng. 12, 439-446
30. Curry, S., Mandelkow, H., Brick, P., and Franks, N. (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 5, 827-835
31. Ober, R. J., Radu, C. G., Ghetie, V., and Ward, E. S. (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13, 1551-1559
32. Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., and Dall'acqua, W. F. (2014) Structural insights into neonatal Fc receptorbased recycling mechanisms. J. Biol. Chem. 289, 7812-7824
33. Zunszain, P. A., Ghuman, J., Komatsu, T., Tsuchida, E., and Curry, S. (2003) Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct. Biol. 3, 6
34. Zunszain, P. A., Ghuman, J., McDonagh, A. F., and Curry, S. (2008) Crystallographic analysis of human serum albumin complexed with 4Z, 15Ebilirubin-IXα. J. Mol. Biol. 381, 394-406
35. Vanzetti, G., Porta, F., Prencipe, L., Scherini, A., and Fraccaro, M. (1979) A homozygote for a serum albumin variant of the fast type. Hum. Genet. 46, 5-9
36. Andersen, J. T., and Sandlie, I. (2009) The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab. Pharmacokinet. 24, 318-332